About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:5823559
Allelic
Composition
Sf3b1tm1.1Mdf/Sf3b1+
Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(Mx1-cre)1Cgn/?
Genetic
Background
involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Sf3b1tm1.1Mdf mutation (2 available); any Sf3b1 mutation (72 available)
Tet2tm1.1Iaai mutation (2 available); any Tet2 mutation (778 available)
Tg(Mx1-cre)1Cgn mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• post-piPC treatment
• block in erythroblast development results in an increase in cells at development stage R2 and a decrease in R4 population in spleen by 12 weeks post-piPC
• transplantation of bone marrow from mutants into lethally irradiated CD45.1 recipient mice that were treated with pIPC results in increasing (46.5% to 90%) donor chimerism beginning at 16 weeks post transplantation as compared to mice carrying only the Sf3b1tm1.1Mdf allele and wild-type
• progressive macrocytic anemia 45 weeks post pIPC treatment
• spleens contain dysplastic megakaryocytes 45 weeks post-piPC treatment
• spleens contain dysplastic erythroid progenitors 45 weeks post-piPC treatment
• observed at 45 weeks post-pIPC injection
• phenotype is increased in severity as compared to mice carrying only the Sf3b1tm1.1Mdf allele
• post-pIPC treatment
• increased percentage of granulocytes in peripheral blood and bone marrow at 45 weeks post-pIPC
• decrease in percentage of B cells in the spleen and bone marrow 45 weeks post-pIPC
• increase in long term repopulating hematopoietic stem cells (LT-HSC) at 12 and 45 weeks as compared to wild-type
• increase in multi-potent progenitors (MPP) in bone marrow 12 weeks post-piPC treatment

immune system
• post-piPC treatment
• transplantation of bone marrow from mutants into lethally irradiated CD45.1 recipient mice that were treated with pIPC results in increasing (46.5% to 90%) donor chimerism beginning at 16 weeks post transplantation as compared to mice carrying only the Sf3b1tm1.1Mdf allele and wild-type
• increased percentage of granulocytes in peripheral blood and bone marrow at 45 weeks post-pIPC
• decrease in percentage of B cells in the spleen and bone marrow 45 weeks post-pIPC

growth/size/body
• post-piPC treatment

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
myelodysplastic syndrome DOID:0050908 OMIM:614286
J:234976


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
03/12/2024
MGI 6.23
The Jackson Laboratory